Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck KGaA Chairman Karl-Ludwig Kley Says Industry Model Not Broken: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

Merck KGaA Global Chariman Karl-Ludwig Kley, while soft-spoken, is fiercely determined to make a lasting impact for stakeholders. Kley contradicts commonly expressed views within the pharma industry on the challenges confronting the industry. At 60, Kley has gathered vast experience across industries having worked at Siemens AG before moving into the pharmaceutical industry with a job at Bayer AG back in 1982. In 2006, Kley joined Merck and a year later he was appointed as its Chairman. On his recent visit to India, he spoke to PharmAsia News' India Bureau on a range of subjects related to the global industry and the shape of emerging markets. In part one of this interview, Kley discussed challenges facing the industry and the role that emerging markets can play. In this second part, he discusses Merck KGaA's pipeline and how the company is positioning itself on the global stage.

You may also be interested in...



Merck KGaA Chairman Karl-Ludwig Kley Says Industry Model Not Broken: An Interview With PharmAsia News (Part 1 of 2)

Merck KGaA Global Chariman Karl-Ludwig Kley, while soft-spoken, is fiercely determined to make a lasting impact for stakeholders. Kley contradicts commonly expressed views within the pharma industrly on the challenges confronting the industry. At 60, Kley has gathered vast experience across industries having worked at Siemens AG before moving into the pharmaceutical industry with a job at Bayer AG back in 1982. In 2006, Kley joined Merck and a year later he was appointed as its Chairman. On his recent visit to India, he spoke to PharmAsia News' India Bureau on a range of subjects related to the global industry and the shape of emerging markets in coming years.

Merck KGaA 2010 Results Marred By Cladribine And Poor OTC Growth

Millipore acquisition boosts 2010 results for Germany's Merck, but pharma strategy remains unclear.

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest News
See All
UsernamePublicRestriction

Register

SC076499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel